Novo Nordisk pharmaceuticals news

Novo Nordisk is discontinuing R&D within inflammatory disorders and will expand R&D in diabetes and obesity. The decision follows a strategic review after Novo discontinued development of its lead compound in the inflammatory disorders space, NN8226. In its 1H14 earnings, Novo disclosed that it discontinued the recombinant human mAb neutralizing IL-20 after the compound missed the primary endpoint in a Phase IIb trial to treat rheumatoid arthritis (RA). The pharma said the decision affects about 400 employees, of which about half will be offered other positions. Novo expects to finalize all clinical activities for inflammatory disorders in the next six months. ...